{
  "kind": "treatment",
  "slug": "flupentixol-depot-depixol-depot",
  "type": "antipsychotic",
  "name": "Flupentixol Depot (Depixol Depot)",
  "summary": "A long-acting injectable typical antipsychotic used primarily for schizophrenia and other psychoses.",
  "description": "Flupentixol depot is a long-acting injectable formulation of the thioxanthene antipsychotic flupentixol, used for maintenance treatment in schizophrenia and other chronic psychotic disorders. It is generally administered intramuscularly every 1–4 weeks, depending on clinical response. Depot administration improves adherence and provides sustained symptom control.",
  "category": "medications/antipsychotics",
  "tags": [
    "typical-antipsychotic",
    "long-acting-injectable",
    "schizophrenia"
  ],
  "metadata": {
    "drug_classes": [
      "Thioxanthene",
      "Typical Antipsychotic"
    ],
    "therapeutic_categories": [
      "Psychosis",
      "Schizophrenia"
    ],
    "mechanism_categories": [
      "Dopamine Blocker"
    ],
    "administration_routes": [
      "Injection"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Depixol Depot"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry"
    ],
    "fda_approval_year": 1968
  },
  "clinical_metadata": {
    "primary_indications": [
      "Psychosis"
    ],
    "off_label_uses": [
      "Bipolar disorder (maintenance)"
    ],
    "contraindications": [
      "Hypersensitivity to flupentixol or formulation components",
      "Acute alcohol intoxication",
      "Comatose states",
      "CNS depression"
    ],
    "monitoring_required": [
      "Extrapyramidal symptoms",
      "Tardive dyskinesia",
      "Metabolic effects",
      "Prolactin levels"
    ],
    "efficacy_rating": {
      "psychosis": 4,
      "overall_tolerability": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "flupentixol depot",
      "depixol depot",
      "long-acting injectable",
      "typical antipsychotic"
    ],
    "synonyms": [
      "flupenthixol decanoate"
    ],
    "common_misspellings": [
      "flupentixole",
      "depixol-deppo"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Schizophrenia",
        "Other chronic psychoses"
      ]
    },
    {
      "type": "mechanism",
      "text": "Blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, reducing positive symptoms of psychosis."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "20–40 mg IM every 2–4 weeks",
        "titrate": "Adjust by 20–40 mg as needed",
        "usual_range": "20–120 mg every 2–4 weeks",
        "max": "400 mg every 2 weeks"
      },
      "geriatric": "Use lowest effective dose",
      "hepatic_impairment": "Use with caution; dose adjustment may be required",
      "renal_impairment": "No specific adjustment; monitor clinical response"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Injection (IM oil solution): 20 mg/mL, 100 mg/mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within several days; full steady state achieved after several weeks of repeated dosing. Duration of effect: 2–4 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "extrapyramidal symptoms",
        "akathisia",
        "drowsiness",
        "dry mouth",
        "constipation"
      ],
      "less_common": [
        "orthostatic hypotension",
        "blurred vision",
        "weight gain"
      ],
      "serious": [
        "tardive dyskinesia",
        "neuroleptic malignant syndrome",
        "QT prolongation"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Increased mortality in elderly patients with dementia-related psychosis.",
      "other": [
        "Monitor for extrapyramidal symptoms and tardive dyskinesia",
        "Use with caution in cardiovascular disease",
        "Avoid abrupt discontinuation"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "CNS depressants",
          "risk": "Enhanced sedation",
          "action": "Use caution"
        },
        {
          "with": "Levodopa",
          "risk": "Reduced antiparkinsonian effect",
          "action": "Avoid combination"
        },
        {
          "with": "QT-prolonging drugs",
          "risk": "Increased arrhythmia risk",
          "action": "Avoid or monitor"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Movement disorders",
        "Metabolic profile",
        "ECG if at risk for QT prolongation"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks",
      "lactation": "Excreted in breast milk; use caution",
      "pediatrics": "Not recommended",
      "geriatrics": "Use with caution; increased sensitivity to adverse effects"
    },
    {
      "type": "tapering",
      "text": "Gradual dose reduction may be required if discontinuing; monitor for relapse."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Depot formulation improves adherence in patients with poor compliance",
        "Usually initiated after tolerability to oral flupentixol is established"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Depixol Depot Prescribing Information",
          "url": "https://www.medicines.org.uk/emc/product/1326"
        },
        {
          "label": "WHO Essential Medicines List",
          "url": "https://www.who.int/medicines"
        }
      ]
    }
  ],
  "seo": {
    "title": "Flupentixol Depot (Depixol Depot): Long-acting Injectable Antipsychotic",
    "description": "Flupentixol Depot is a long-acting injectable typical antipsychotic for maintenance treatment of schizophrenia and chronic psychosis."
  }
}
